Histological tumor typing in the age of molecular profiling

Pathology Research and Practice

Volumn 211, Issue 12, 2015, Pages 897-900

  Klauschen, Frederick ^a,b   Heim, Daniel ^a   Stenzinger, Albrecht ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Einstein Foundation Berlin   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Basket trials; Cancer; Clinical trials; Molecular pathology; Mutational profiling; Next generation sequencing; Precision oncology; Systems medicine

Indexed keywords

CRIZOTINIB;

ACUTE MYELOBLASTIC LEUKEMIA; BREAST CARCINOMA; CLINICAL TRIAL (TOPIC); COLORECTAL CARCINOMA; ENDOMETRIUM CARCINOMA; GENE DELETION; GENE INSERTION; GENETIC SIMILARITY; GLIOBLASTOMA; HEAD AND NECK CARCINOMA; HISTOLOGY; HUMAN; KIDNEY CARCINOMA; LUNG CARCINOMA; MELANOMA; NON SMALL CELL LUNG CANCER; OVARY CARCINOMA; REVIEW; SOMATIC MUTATION; STOMACH CARCINOMA; THYROID CARCINOMA; TUMOR CLASSIFICATION; GENE EXPRESSION PROFILING; GENETICS; HIGH THROUGHPUT SEQUENCING; NEOPLASM; PERSONALIZED MEDICINE; PROCEDURES;

GENE EXPRESSION PROFILING; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; NEOPLASMS; PRECISION MEDICINE;

EID: 84941342871     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2015.08.001     Document Type: Review

References (28)

1. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012, 489:519-525.
2. Baselga J. Bringing precision medicine to the clinic: from genomic profiling to the power of clinical observation. Ann. Oncol. 2013, 24:1956-1957.
3. Budczies J., Bockmayr M., Denkert C., Klauschen F., Lennerz J.K., Györffy B., Dietel M., Loibl S., Weichert W., Stenzinger A. Classical pathology and mutational load of breast cancer - integration of two worlds. J. Pathol. Clin. Res. 2015, (in press).
4. Ciriello G., Miller M.L., Aksoy B.A., Senbabaoglu Y., Schultz N., Sander C. Emerging landscape of oncogenic signatures across human cancers. Nat. Genet. 2013, 45:1127-1133.
5. Dienstmann R., Rodon J., Barretina J., Tabernero J. Genomic medicine frontier in human solid tumors: prospects and challenges. J. Clin. Oncol. 2013, 31:1874-1884.
6. Garraway L.A., Lander E.S. Lessons from the cancer genome. Cell 2013, 153:17-37.
7. Garraway L.A., Verweij J., Ballman K.V. Precision oncology: an overview. J. Clin. Oncol. 2013, 31:1803-1805.
8. Heim D., Budczies J., Stenzinger A., Treue D., Hufnagl P., Denkert C., Dietel M., Klauschen F. Cancer beyond organ and tissue specificity: next-generation-sequencing gene mutation data reveal complex genetic similarities across major cancers. Int. J. Cancer 2014, 35:2362-2369.
9. Kim E.S., Herbst R.S., Wistuba I.I., Lee J.J., Blumenschein G.R., Tsao A., Stewart D.J., Hicks M.E., Erasmus J., Gupta S., Alden C.M., Liu S., Tang X., Khuri F.R., Tran H.T., Johnson B.E., Heymach J.V., Mao L., Fossella F., Kies M.S., Papadimitrakopoulou V., Davis S.E., Lippman S.M., Hong W.K. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011, 1:44-53.
10. Klauschen F. Mutational tumor profiles beyond organ and tissue specificity: implications for diagnostics and clinical study design. Pathologe 2014, 35(Suppl. 2):277-280.
11. Klauschen F., Andreef M., Keilholz U., Dietel M., Stenzinger A. The combinatorial complexity of cancer precision medicine. Oncoscience 2014, 1:504-509.
12. Klein C.A. Selection and adaptation during metastatic cancer progression. Nature 2013, 501:365-372.
13. Budczies J., von Winterfeld M., Klauschen F., Bockmayr M., Lennerz J.K., Denkert C., Wolf T., Warth A., Dietel M., Anagnostopoulos I., Weichert W., Wittschieber D., Stenzinger A. The landscape of metastatic progression patterns across major human cancers. Oncotarget 2015, 6:570-583.
14. Liberzon A., Subramanian A., Pinchback R., Thorvaldsdottir H., Tamayo P., Mesirov J.P. Molecular signatures database (MSigDB) 3.0. Bioinformatics 2011, 27:1739-1740.
15. Lopez-Chavez A., Thomas A., Rajan A., Raffeld M., Morrow B., Kelly R., Carter C.A., Guha U., Killian K., Lau C.C., Abdullaev Z., Xi L., Pack S., Meltzer P.S., Corless C.L., Sandler A., Beadling C., Warrick A., Liewehr D.J., Steinberg S.M., Berman A., Doyle A., Szabo E., Wang Y., Giaccone G. Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. J. Clin. Oncol. 2015, 33:1000-1007.
16. MacConaill L.E. Existing and emerging technologies for tumor genomic profiling. J. Clin. Oncol. 2013, 31:1815-1824.
17. McDermott U., Downing J.R., Stratton M.R. Genomics and the continuum of cancer care. N. Engl. J. Med. 2011, 364:340-350.
18. Menzies A.M., Long G.V. Systemic treatment for BRAF-mutant melanoma: where do we go next?. Lancet Oncol. 2014, 15:e371-e381.
19. Mills G.B. An emerging toolkit for targeted cancer therapies. Genome Res. 2012, 22:177-182.
20. Prahallad A., Sun C., Huang S., Di Nicolantonio F., Salazar R., Zecchin D., Beijersbergen R.L., Bardelli A., Bernards R. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012, 483:100-103.
21. Shaw A.T., Kim D.W., Nakagawa K., Seto T., Crino L., Ahn M.J., De Pas T., Besse B., Solomon B.J., Blackhall F., Wu Y.L., Thomas M., O'Byrne K.J., Moro-Sibilot D., Camidge D.R., Mok T., Hirsh V., Riely G.J., Iyer S., Tassell V., Polli A., Wilner K.D., Janne P.A. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 2013, 368:2385-2394.
22. Sobin L.H. TNM: principles, history, and relation to other prognostic factors. Cancer 2001, 91:1589-1592.
23. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., Fujiwara S., Watanabe H., Kurashina K., Hatanaka H., Bando M., Ohno S., Ishikawa Y., Aburatani H., Niki T., Sohara Y., Sugiyama Y., Mano H. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
24. Stenzinger A., Lennerz J.K., Weichert W., Klauschen F. Basket trials: just the end of the first quarter. J. Clin. Oncol. 2015, 33:2823-2824.
25. Hyman D.M., Puzanov I., Subbiah V., Faris J.E., Chau I., Blay J.Y., Wolf J., Raje N.S., Diamond E.L., Hollebecque A., Gervais R., Elez-Fernandez M.E., Italiano A., Hofheinz R.D., Hidalgo M., Chan E., Schuler M., Lasserre S.F., Makrutzki M., Sirzen F., Veronese M.L., Tabernero J., Baselga J. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med. 2015, 373:726-736.
26. Stenzinger A., von Winterfeld M., Aulmann S., Warth A., Weichert W., Denkert C., Ruschoff J., Dietel M., Klauschen F. Quantitative analysis of diagnostic guidelines for HER2-status assessment. J. Mol. Diagn. 2012, 14:199-205.
27. Watson I.R., Takahashi K., Futreal P.A., Chin L. Emerging patterns of somatic mutations in cancer. Nat. Rev. Genet. 2013, 14:703-718.
28. Willyard C. 'Basket studies' will hold intricate data for cancer drug approvals. Nat. Med. 2013, 19:655.